Assisted Reproductive Technology Outcomes After Ethanol Sclerotherapy in Poor Responder Patients with Endometriomas: A Before-After Clinical Trial

Ghasemi F, Farah Ghasemi, Kashani L, Ladan Kashani, Moini A, Ashraf Moini, Maryam Farid Mojtahedi, Farid Mojtahedi M, Shahhosseini R, Roza Shahhosseini, Alemohammad F, Farzaneh Alemohammad
Journal of reproduction & infertility · 2024 · vol. 25(3) , pp. 224–230 · doi:10.18502/jri.v25i3.17017 · PMID:39830317 · PMC11736268 · W4404447243
Non-randomised trial OA: gold CC0
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

Ethanol sclerotherapy for endometriomas in poor responders improved antral follicle count, AMH, embryo yield, and pain symptoms before assisted reproductive technology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This before-after clinical trial evaluated assisted reproductive technology outcomes in poor responder patients who had endometriomas treated with ethanol sclerotherapy, comparing ART results before versus after the intervention. The study reported the post-sclerotherapy ART outcomes in this specific population, focusing on measures used to characterize treatment performance. A key limitation is the before-after design, which lacks randomization and control for potential temporal or selection effects. This paper is centrally about endometriosis — it examines ART outcomes after ethanol sclerotherapy in poor responder patients with endometriomas.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: The purpose of the present study was to investigate the assisted reproductive technology (ART) outcomes after ethanol sclerotherapy (EST) in poor responder patients with endometriomas. METHODS: In this before-after clinical trial, the outcomes of ART of 31 poor responders with endometriomas were evaluated after EST between July 2023 to March 2024. These patients had undergone ART at least in one cycle before and did not respond well. Recurrence rate, antral follicle count (AFC), anti-Müllerian hormone (AMH), and relief of symptoms including dysmenorrhea and abnormal uterine bleeding (AUB) were evaluated before the procedure. Follow-up assessments were conducted two and six weeks after the procedure for evaluating the complications. Fisher's exact test, chi-square test, and paired sample t-test were used for statistical analysis using SPSS 24. RESULTS: In this study, the levels of AFC and AMH increased significantly after endometrioma stripping therapy (p<0.05). Additionally, the number of embryos obtained increased significantly, indicating potential improvement in oocyte quality. There was a significant reduction in pelvic pain scores (p=0.001), as well as a notable decrease in dysmenorrhea (p=0.02) and dyspareunia (p=0.001). Moreover, 16.12% of patients reported recovery from intermenstrual bleeding. However, no significant difference was observed in the amount of gonadotropin used (p=0.56). CONCLUSION: EST is an appropriate and safe procedure before ART for poor responders who have endometriomas and can be a replacement for surgery among selected patients.
Full text 1,753 characters · extracted from oa-doi-fallback · click to expand
Publication Journal of Reproduction & Infertility Record type Journal article Published 17 November 2024 Authors Farah Ghasemi | Ladan Kashani | Ashraf Moini | Maryam Farid Mojtahedi | Roza Shahhosseini | Farzaneh Alemohammad The publisher of this work supports multiple resolution. The work is available from the following locations: {'doi': '10.18502/jri.v25i3.17017', 'member_id': '7770', 'member': 'Knowledge E DMCC', 'container-title': 'Journal of Reproduction & Infertility', 'primary-resource': 'https://publish.kne-publishing.com/index.php/JRI/article/view/17017', 'tld': 'kne-publishing.com', 'clearbit-logo': '/static/no_logo.svg', 'coaccess': [], 'multiple-resolution': [{'url': 'https://www.jri.ir/article/140239', 'tld': 'jri.ir', 'clearbit-logo': '/static/no_logo.svg'}], 'type': 'JOURNAL ARTICLE', 'published_date': '17 November 2024', 'publication': 'Journal of Reproduction & Infertility', 'title': 'Assisted Reproductive Technology Outcomes After Ethanol Sclerotherapy in Poor Responder Patients with Endometriomas: A Before-After Clinical Trial', 'name': None, 'id': None, 'location': None, 'display_doi': 'https://doi.org/10.18502/jri.v25i3.17017', 'grant_info': None, 'grant_info_funders': None, 'grant_info_funder_ids': '', 'grant_info_type': None, 'multiple_lead_investigators': [], 'multiple_co_lead_investigators': [], 'multiple_investigators': [], 'finances': [], 'project_description': None, 'award_amount': None, 'award_start': None, 'funding_scheme': None, 'internal_award_number': None, 'editors': None, 'authors': 'Farah Ghasemi | Ladan Kashani | Ashraf Moini | Maryam Farid Mojtahedi | Roza Shahhosseini | Farzaneh Alemohammad', 'chairs': None, 'supplementary_ids': None} https://doi.org/10.18502/jri.v25i3.17017 JSON XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriomadysmenorrheadyspareunia

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:47:34.457808+00:00
License: CC0 · commercial use OK